Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).

Beta-blockers safe for use in ECMO patients

10 Aug 2019

The use of beta-blockers in hypoxaemic patients receiving veno-venous extracorporeal membrane oxygenation (V–V ECMO) safely and modestly increases oxygen saturation, a recent study has found.

Researchers retrospectively examined 33 patients (median age, 49 years; 55 percent male) who received beta-blockers for a median of 4 days while on V–V ECMO. The primary safety outcome was the occurrence of a composite of bradycardia or hypotension requiring intervention, as well as the need for resuscitation, the discontinuation of beta-blockers during the first 5 days and an unexplained spike in serum lactate.

A total of 15 safety events in 13 patients (39 percent) were reported. Majority (n=9) required an increase in norepinephrine dose though only one had to discontinue beta-blocker medication. Other safety endpoints included bradycardia with need for intervention (n=2), new rise in lactate levels (n=2), new septic shock (n=1) and the risk of adverse drug interactions (n=1).

In terms of efficacy, there was a significant increase in oxygen saturation in the first 12 hours after beta-blocker initiation (92 percent to 96 percent; p=0.01) accompanied by a decrease in heart rate (105 to 93 bpm; p<0.01). There were no such changes in lactate levels, norepinephrine dose and mean arterial pressure.

“In our experience, [beta-blocker] therapy was well tolerated and resulted in a significant increase in arterial oxygenation in patients on V-V ECMO,” said researchers. “Future prospective studies should be performed to clarify the benefit of this strategy in this setting.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2019
New drug applications approved by US FDA as of 16 - 30 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approval. Supplemental approvals may have occurred since the original approval date.
05 Aug 2019
Use of alpha blockers in the treatment of hypertension in women is associated with an increased risk of hypotension and related events as compared with other blood pressure-lowering drugs, as reported in a recent study.
Dr. Bryan Li, Dr. Gerry Kwok, Dr. Thomas Yau, 07 Aug 2019

Case 1: A 59-year-old gentleman with advanced HCC was referred to our centre for management. He had a history of diabetes, hypertension and ischaemic heart disease. He was a nondrinker and not a carrier of hepatitis B or C.

Case 2: A 65-year-old man with a history of alcoholic cirrhosis and oesophageal varices was found to have rising AFP levels on routine follow-up. He also had a 3-year history of diabetes and was on diet control, with an HbA1c of 6.2 percent and fasting glucose of 6.8 mmol/L. He did not need any diabetic medications.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).